Eagle Pharmaceuticals Inc EGRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EGRX is a good fit for your portfolio.
News
-
EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options
-
Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX
-
EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit
-
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)
-
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024
-
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX
-
EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit
-
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline
Trading Information
- Previous Close Price
- $4.16
- Day Range
- $4.07–4.28
- 52-Week Range
- $4.05–30.40
- Bid/Ask
- $4.16 / $4.18
- Market Cap
- $54.04 Mil
- Volume/Avg
- 87,511 / 176,021
Key Statistics
- Price/Earnings (Normalized)
- 0.89
- Price/Sales
- 0.21
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 18.11%
Company Profile
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 134
- Website
- http://www.eagleus.com
Comparables
Valuation
|
Metric
|
EGRX
|
CRNX
|
PNT
|
|---|---|---|---|
Price/Earnings (Normalized) | 0.89 | — | 11.36 |
Price/Book Value | 0.22 | 5.33 | 3.12 |
Price/Sales | 0.21 | 609.51 | 5.50 |
Price/Cash Flow | 1.13 | — | 13.90 |
Price/Earnings
EGRX
CRNX
PNT
Financial Strength
|
Metric
|
EGRX
|
CRNX
|
PNT
|
|---|---|---|---|
Quick Ratio | 1.52 | 12.92 | 9.01 |
Current Ratio | 2.16 | 13.07 | 9.14 |
Interest Coverage | 5.39 | — | — |
Quick Ratio
EGRX
CRNX
PNT
Profitability
|
Metric
|
EGRX
|
CRNX
|
PNT
|
|---|---|---|---|
Return on Assets (Normalized) | 6.32% | −38.81% | 20.67% |
Return on Equity (Normalized) | 10.51% | −44.79% | 23.56% |
Return on Invested Capital (Normalized) | 9.73% | −45.62% | 23.38% |
Return on Assets
EGRX
CRNX
PNT
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Kbfwkgdyp | Tlb | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Snlbbxvnpn | Nkqcbb | $70.8 Bil | |
HLN
| Haleon PLC ADR | Tfslgymb | Yzht | $38.2 Bil | |
VTRS
| Viatris Inc | Vtrscfzwn | Btgh | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Hzhsqkcr | Hkz | $12.5 Bil | |
CTLT
| Catalent Inc | Jwgltdwb | Yrhbw | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Gxgcmhxt | Ncnw | $4.3 Bil | |
CURLF
| Curaleaf Holdings Inc | Qxskpslbd | Kmzsw | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Mbjfrrbp | Rxhqrp | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Hmjgywdlb | Nwky | $2.9 Bil |